Urology Calculators
22 calculators
- IPSS — International Prostate Symptom Score7-item questionnaire for lower urinary tract symptoms (LUTS) in BPH. Guides treatment decisions.
- PSA Density CalculatorPSA Density = PSA / Prostate Volume (from TRUS). Helps differentiate benign BPH from prostate cancer.
- Renal Stone Risk AssessmentClinical risk stratification for renal/ureteric stone recurrence to guide metabolic workup and prevention.
- EAU Bladder Cancer Recurrence Risk (EORTC)EORTC-based risk stratification for non-muscle-invasive bladder cancer (NMIBC) recurrence and progression.
- OAB-V8 — Overactive Bladder Questionnaire8-item validated questionnaire for diagnosis and monitoring of overactive bladder (OAB).
- IGCCCG Risk Classification — Testicular CancerInternational Germ Cell Cancer Collaborative Group (IGCCCG) risk classification for testicular germ cell tumours.
- Contrast Nephropathy Risk ScoreMehran risk score for contrast-induced acute kidney injury (CI-AKI) after contrast exposure.
- Gleason Score / Grade Group for Prostate CancerPathological grading of prostate cancer. Modern reporting uses Grade Groups 1–5 (from Gleason sum 6 to 10). Guides treatment decision from active surveillance to radical therapy.
- TWIST Score for Testicular TorsionTesticular Workup for Ischaemia and Suspected Torsion (TWIST) score to guide immediate scrotal exploration vs USS in suspected testicular torsion.
- Prostate Cancer Risk Stratification (NICE / EAU)Risk stratification for localised/locally advanced prostate cancer using PSA, Gleason grade group, and clinical stage to guide treatment planning.
- UCSF-CAPRA Score for Prostate CancerCancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence, metastasis, and cancer-specific death after prostatectomy. Score 0–2 = low risk; 3–5 = intermediate; 6–10 = high risk.
- PSA Doubling Time (PSADT) CalculatorCalculates PSA velocity and doubling time for men with prostate cancer or rising PSA. PSADT <10 months after prostatectomy suggests systemic progression. Requires ≥2 PSA measurements.
- D'Amico Risk Classification for Prostate CancerStratifies prostate cancer risk into low, intermediate, and high categories based on PSA, Gleason score, and clinical T stage. Widely used to guide initial treatment decisions.
- RENAL Nephrometry ScoreStandardised scoring of renal tumour anatomy for surgical planning. Predicts operative complexity and guides decision between partial and radical nephrectomy.
- IPSS (International Prostate Symptom Score)Assesses lower urinary tract symptom (LUTS) severity in BPH. Guides watchful waiting vs medical vs surgical management.
- PSA Velocity and PSA DensityCalculates PSA velocity (rate of PSA rise per year) and PSA density. PSA velocity >0.75 ng/mL/year or PSA density >0.15 ng/mL/mL suggests cancer risk.
- Kidney Stone Size vs Spontaneous Passage RateEstimates spontaneous stone passage rate based on stone size and location. Guides conservative vs interventional management (SWL, URS, PCNL).
- Estimated Bladder Capacity (Age-based)Estimates expected bladder capacity by age. Used in urodynamics and to assess functional bladder capacity.
- Renal Stone Recurrence Risk AssessmentIdentifies risk factors for renal stone recurrence to guide metabolic evaluation and preventive treatment.
- CROES PCNL Outcome ScorePredicts stone-free rate after percutaneous nephrolithotomy (PCNL) based on patient and stone characteristics.
- Testicular Torsion Probability Score (TWIST)Predicts probability of testicular torsion to guide immediate surgery vs scrotal USS. High score = immediate exploration without USS delay.
- ICIQ-UI Short Form (Urinary Incontinence)International Consultation on Incontinence Questionnaire (ICIQ-UI SF) scores urinary incontinence frequency, amount, and impact. Score 0-21.